Also known as: Fusion Pharmaceuticals
Fusion Pharmaceuticals is a biopharmaceutical company focused on targeted alpha-particle radiotherapeutics for cancer treatment. The company describes itself as a spinout from the Centre for Probe Development and Commercialization at McMaster University and positions its platform around linking medical isotopes to targeting molecules. It is based in Hamilton, Ontario.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
Radiopharmaceuticals are emerging as a promising therapeutic class in oncology, with theranostic approaches combining diagnostics and treatment gaining particular attention. Major pharmaceutical companies have invested billions in acquisitions while venture financing reached record levels.
